Mal de Meleda – through history and today by Ana Bakija-Konsuo
79ACTA DERMATOVENEROLOGICA CROATICA
Mal de Meleda – Through History and Today
Ana Bakija-Konsuo
”Cutis” Clinic for Dermatovenerology, Dubrovnik, Croatia
Corresponding author:
Ana Bakija-Konsuo, MD, PhD





Received: June 13, 2013
Accepted: April 15, 2014
SUMMARY Meleda disease is an indigenous dermatological disease 
classified as a hereditary palmoplantar keratoderma. The disease was 
first described on the island of Mljet, Croatia, by Luko Stulli in 1826. We 
present a historical review of the literature data throughout the centuries 
till today. Recently, the gene responsible for the disease has been identi-
fied on chromosome 8qter within the cluster of Ly-6 homologous human 
genes. Various mutations in the secreted LY6/PLAUR-related protein1 
gene (SLURP1) located on the aforementioned chromosome were iden-
tified as the cause of the disease. Due to similarity between the islands 
of Malta and Mljet, we are proud of the fact that, to the credit of Croatian 
researchers and scientists, Mal de Meleda entered the international sci-
entific literature under that very name and has preserved it until today.
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MAl de MeledA – in THe pAST
Meleda disease is an indigenous dermatological 
disease classified as hereditary palmoplantar kerato-
derma (autosomal recessive). For more than two cen-
turies, it has occurred among the inhabitants of the 
island of Mljet. It was first reported by Luko Stulli, a 
physician, philosopher, and poet from Dubrovnik, in 
the letter from directorial Florentine Anthology, of 29 
September, 1826. In his article titled “Di una varieta 
cutanea”, still kept today in the “Antologia di Firenze 
fasc. 71/72”, Stulli, among other things, states:
“A village on the island of Mljet is a site of a skin vari-
ety observed on the extremities of some inhabitants and 
it deserves to be mentioned. Eleven persons, belonging 
to three families, have displayed non-natural structure 
of the skin integument in the palm of hands, palmar 
fascia of the fingers, soles and heels, i.e. the parts of the 
human body that nature has foreseen to be used. The 
history of this anomaly does not go back farther than 
half a century and no guesses can be made as to when 
and how that disease first appeared on the island and 
who was the first to fall ill from it. It has only been as-
serted that during those fifty years it has appeared 
always in the same form, so it can be concluded that 
it was not much different during previous times. New-
born children have on their palms undoubted signs of 
this skin lesion which over the years extends to finally 
take the appearance of a thick, yellowish layer of tal-
low, showing crust resistance when touched and due 
to erosions being similar to cork, and the said places do 
not sweat nor vaporise and are insensitive. The thicken-
ing of the cuticle itself appears additionally on elbows, 
as well as on knees, which are frequently covered with 
scales and papillary efflorescence’s, hands and feet are 
cramped, as is typical in burns, affected parts provoke 
feelings of aversion while not even the strongest blow is 
enough to cause a sensation of pain in them. They con-
tain no wounds at all. The impossibility to secrete sweat 
on the surface causes nasty stench. The issue in our case 
is an innate, organic and only in certain places obvious 
and in certain boundaries limited disease which is not 
Acta Dermatovenerol Croat                     2014;22(2):79-84                HISTORY OF MEDICINE
80 ACTA DERMATOVENEROLOGICA CROATICA
overstepped over the course of time, nor by character 
differences, and neither by the influence of effective 
ancillary circumstances. It appears both in men and in 
women. Any suspicion of infectious spreading would 
be inopportune. The very appearance of the disease is 
repulsive; ability of action in hands is reduced, with fin-
gers, ring and baby fingers in particular, in the position 
of strengthened and constant bend.”(1-5).
According to legend, the first case of the disease 
happened in a respectable family when a family el-
der, because of some local feud – the issue was al-
legedly the familial and local prestige regarding the 
selection of the seat of the new parish – witnessed by 
an entire procession, desecrated the eucharist sacra-
ment by grabbing it and smashing it on the ground 
and trampling it underfoot. As of that moment, he 
and his descendants were permanently branded. 
Members of his family bear on their hands an indel-
ible mark, visible to everyone as the lasting symbol 
of God’s punishment. Even today, in the deserted 
chapel there is a silver platelet on the Baroque altar 
painting of the Madonna showing an arm with visible 
skin lesions (6,7).
The island of Mljet itself was used by the Dubrovnik 
Republic as a quarantine. Interestingly enough, 
Hansen’s disease, brought to Dubrovnik from Rome 
in 1500, was eradicated by the Republic within two 
weeks, since all suspicious patients were promptly 
sent to Mljet. Today’s settlement of Korita was, accord-
ing to legend, named ”korota”, which means ”mourn-
ing”, following one such pestilence when the village 
was catastrophically desolated (7,8). The locals called 
the disease “guba” (leprosy), which was traditionally 
said to have arrived from Herzegovina to the village 
of Maranovići. It was known among the people that it 
was not directly passed from parents to children, and 
that the diseased gave birth to the healthy and the 
healthy gave birth to the diseased, so it occurred in 
the third and in the fourth generation (2,4,9).
During the 19th and 20th centuries, Meleda dis-
ease, named after one of the most beautiful Croatian 
islands located to the north-east of Dubrovnik, was 
of scientific interest to numerous physicians of that 
age, particularly to dermatovenerologists. As early 
as 1839, Behrend calls the disease “Morbo di Melada” 
(“Melada” is the Italian name for the island of Molat, 
near Zadar, therefore Behrend’s naming is incorrect) 
(3,10). More than half a century later, in 1896, a mu-
nicipality doctor from Janjina, Dr Oscar Hovorka pl. 
Zderas created confusion by claiming that he had 
discovered the endemic source of Hansen’s disease. 
Hovorka described several cases from the settlement 
of Maranovići, two from Babino polje, and two from 
Blato (11). This was at the time when leprosy was be-
ing discovered across Bosnia and Dalmatia. One year 
later, Dr Hovorka visited Mljet together with Ehlers, a 
leprologist from Copenhagen, and they jointly estab-
lished that the issue at hand was not leprosy, but a 
special skin disease of the palms and feet which they 
correctly named “Mal de Meleda” (12).
During and Unna, two renowned dermatovener-
ologists, label the disease a separate entity, keratoma 
palmare et plantare hereditarium, but their naming 
was not approved by other dermatovenerologists of 
that time (13). Gans stated that the disease cannot be 
attributed to hereditary keratoderma with certainty, 
Figure 1. Clinical appearance of changes of the up-
per extremities in a patient with Mal de Meleda
Figure 2. Clinical appearance of changes of the lower 
extremities in a patient with Mal de Meleda.
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unlike Vohwinkel who claimed the opposite (14). Sie-
mens energetically advocated the separate status of 
the Mljet disease, calling it Keratosis palmoplantaris 
transgrediens, from palmoplantar keratosis of the 
Unna-Thost type (15,16).
In 1931, Moncorps, in his monographic narrative 
“Keratosen” found in Jadassohn’s extensive “Handbu-
ch der Haut- und Geschlechtskrankheiten”, again 
blurred the boundaries which had been created 
around Meleda disease as a separate entity, and this 
despite Siemens’ claim of the transgrediency of skin 
lesions (from palms and soles) and the assumption of 
its non-dominant inheritance (17). Niles and Klump 
strongly advocated that Meleda disease was an inde-
pendent entity, and so the disease entered the global 
literature mostly thanks to the research and works 
of Kogoj, as emphasised by Hoede in his writings in 
1941 (18,19). Kogoj stayed in Mljet during 1930 and 
twice more, in 1946 and 1960, along with his student 
Bošnjaković (20,21). Bošnjaković described the clini-
cal features in detail and inferred the recessive man-
ner of inheritance (2,6,22). Kogoj named Meleda dis-
ease Keratosis extremitatum hereditaria progrediens, in 
order to emphasize the main features of the disorder, 
primarily the location of pathological changes ex-
tending to the upper and lower extremities, the he-
reditary character, and the expansion of lesions from 
distal parts of limbs, i.e. palms and soles to under-
arms, knees, and thighs up to the inguinal and gluteal 
region (20). He argued in favor of the term progredi-
ens, which indicates the dynamics of the pathological 
process, as opposed to Siemens’ term transgrediens, 
which indicates a present state and is static (21). Ac-
cording to the works of Kogoj and Bošnjković, patients 
at the beginning of the past century complained of 
painful cracks onto which they poured tallow; in this 
way they would heal in two days (4).
During 1969 and 1970, Schnyder et al. determined 
that brachyphalangia is an obligatory symptom of 
Meleda disease (23,24). The monitoring of radiologi-
cal changes during ten years in patients with Meleda 
disease was described by Kačić et al. in 1981, who 
confirmed the conclusions of a research conducted 
by Kačić et al. in 1969 which showed that osteopo-
rosis, cystiform osteolysis, and acroosteolysis were 
characteristic, but still facultative symptoms of the 
Meleda disease. The authors established that phalan-
geal changes, such as bilateral brachimesophalangy 
of the fifth finger of the hand and the second, third, 
and fourth finger of the foot, as well as the bilateral 
brachihypophalangy of the fifth finger, are obligatory 
anomalies and thus can be considered pathognomic 
(25,26). In 1983, Topić and Šalamon found that the 
inflammation of the corner of the lips (cheilitis an-
gularis) is an obligatory symptom and that furrowed 
tongue (lingua plicata) is much more common in pa-
tients suffering from the Meleda disease than in the 
control group (27).
Interestingly, according to unverified informa-
tion dating from the beginning of the 19th century, 
a similar disease also occured in Pelješac, Konavle, 
on the island of Silba, Molat, Premuda and probably 
in Zadar (9). The disease is not exclusively found on 
the island of Mljet. In the past few decades, several 
cases of this disease have also been reported in some 
Mediterranean countries and in the Middle East, in 
places that were on the trade routes of the medieval 
Republic of Dubrovnik which incorporated the island 
(28-33). However,  Meleda disease has been recently 
observed in more distant countries such as in Chinese 
families in Taiwan, in Pakistan, or in Korea, currently 
the farthest country from the endemic areas and with 
no connection in history (34-36).
MAl de MeledA - TodAY
The most current field research on the territory 
of the Republic of Croatia was conducted by Bakija-
Konsuo et al. in 2001, when they, having found all 
the patients (12 living cases with the reconstruction 
of 8 genealogies), thoroughly described all the clini-
cal, patohistological, and ultrastructural features of 
the Meleda disease (37). The disease begins as early 
as in the first weeks or months of life. The first mani-
festation is redness on the palms and soles (38,39). 
It is clinically characterized by diffused thickening 
of the palms and soles with increased perspiration, 
dystrophic nail changes, and contractures in the fin-
gers of hands (Figure 1). In addition to these so-called 
obligatory symptoms, in certain patients we can find 
perioral erythema, Gothic palate, tongue lesions, etc., 
as so-called facultative symptoms. The mental devel-
opment of patients is normal. In time, lesions gradu-
ally extend to the dorsal sides of elbows and knees 
(thus the transgrediens attribute) (Figure 2). Sensibil-
ity is mostly preserved, while the sense of heat and 
pain is disturbed above thicker layers. The affected 
skin sometimes itches, with heavy perspiration and 
an unpleasant odor. If the keratotic layers are gradu-
ally removed, a gentle and mildly pink surface with a 
reticular pattern appears (37-40).
It should be noted that the longevity of the dis-
ease was influenced by its occurrence on an island 
with a small number of inhabitants (about 1000),with 
a high level of reproductive isolation and low immi-
gration rates throughout recent history, which fa-
vored consanguinity, high levels of kinship among 
the population, and the maintenance of a relatively 
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high allele frequency in the island’s population, and 
probably even its increase over time (41-44).
Meleda disease is still being investigated today, 
as can be seen from the genetic research of Fisher 
et al., who managed to localize the gene responsible 
for the disease on the 8qter chromosome within the 
cluster of Ly-6 homologous human genes (45). Mu-
tations in the secreted LY6/PLAUR-related protein1 
gene (SLURP-1) located on aforementioned chromo-
some were identified as the cause of Mal de Meleda 
(46). Mapping to this region has been confirmed by 
Bouadjar et al. and by Pate et al. (47,48). 
SLURP-1 (previously known as ARS Component 
B) regulates keratinocyte proliferation, apoptosis, 
and differentiation, and is involved in the regulation 
of cutaneous inflammation (49,50). The amino acid 
composition of SLURP-1 is homologous to that of 
the single domain frog cytotoxin and snake venom 
neurotoxins, such as α-bungarotoxin (46). Keratino-
cytes secrete SLURP-1 protein, which is detectable in 
plasma and urine where it was first isolated (51). The 
physiological role of SLURP-1 remained to be discov-
ered, so further investigation will be needed in order 
to fully elucidate its effect on keratinocytes (50,52).
Favre et al. have demonstrated that SLURP-1 is a 
late marker of epidermal differentiation and is pres-
ent in all analyzed biological fluids (saliva, sweat, 
tears, and urine). They showed that SLURP-1 is almost 
undetectable in the skin or sweat of patients with 
Mal de Meleda. The presence of SLURP-1 in several 
biological fluids suggests that an immunologic Mal 
de Meleda pre-diagnosis could be performed with-
out any invasive procedures. Whether SLURP-1 has a 
specific function in these biological fluids is still un-
known (51).
SLURP-1 potentiates the human α7 nicotinic ace-
tylcholine receptors (nAchR) that are present in kera-
tinocytes, and plays an important role in the differen-
tiation of stratified squamous epithelium (50,53). It is 
a secreted epidermal neuromodulator which is likely 
essential for both epidermal homeostasis and inhi-
bition of TNF alpha release by macrophages during 
wound healing. This explains both the hyper prolifer-
ative as well as the inflammatory clinical phenotype 
of Mal de Meleda (52).
Three different homozygous mutations (a dele-
tion, a nonsense, and a splice site mutation) were 
detected in 19 families of Algerian and Croatian ori-
gin, suggesting founder effects. Moreover, one of the 
common haplotypes presenting the same mutation 
was shared by families from both populations. Secret-
ed and receptor proteins of the Ly-6/uPAR superfam-
ily have been implicated in transmembrane signal 
transduction, cell activation, and cell adhesion. This is 
the first instance of a secreted protein being involved 
in a palmoplantar keratoderma (46). So far, a total of 
11 mutations associated with the inception of Me-
leda disease have been found in the gene encoding 
SLURP-1, and with a few exceptions, all the mutations 
induce the same clinical features, regardless of differ-
ences in age or geographical origin (54-58). 
ConClUSionS
The writers of classical antiquity called this island 
Melite, Meleta, Melada, or Melta, the meaning of 
which in Greek language corresponds the Latin word 
mell, which means honey. Once numerous honeybee 
swarms in Mljet’s forests gave the island its name, just 
as with the larger and much more famous island of 
Malta (59). It is Malta that, due to the similarity be-
tween the two toponyms, took and still lays claim to 
the two most important legends of Mljet – the legend 
of Odysseus and the nymph Calypso and the legend 
of St Paul’s shipwreck on his journey to Rome. This 
makes us even prouder that, to the credit of Croatian 
researchers and scientists, Mal de Meleda entered 
the international scientific literature under that very 
name and has preserved it until today (3,9,10,20,23,
24,37,39,46). 
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